Notable Upgrades: Broadcom (BRCM), Oracle (ORCL), Retrophin (RTRX), Tekmira Pharmaceuticals (TKMR), Ambarella (AMBA)

Analysts at Nomura are out with a report this morning upgrading shares of Broadcom Corp. (BRCM) with a ‘Buy‘ from ‘Neutral‘ rating.

Broadcom Corp. shares are currently priced at 40.71x this year’s forecasted earnings, which makes them quite expensive compared to the industry’s 5.40x earnings multiple. Ticker has a forward P/E of 14.45 and t-12 price-to-sales ratio of 3.05. EPS for the same period is $1.08.

In the past 52 weeks, shares of Irvine California-based company have traded between a low of $28.86 and a high of $46.31 and are now at $43.97. Shares are up 40.87% year-over-year ; down 0.65% year-to-date.

Analysts at RBC Capital Markets upgraded their rating on the shares of Oracle Corporation (ORCL). In a research note published on Monday, the firm lifted the name with a ‘Outperform‘ from ‘Sector Perform‘ rating and set a 12-month base case estimate of $50 from $48 per share.

On valuation measures, Oracle Corp. shares are currently priced at 18.16x this year’s forecasted earnings, compared to the industry’s 34.96x earnings multiple. Ticker has a PEG and forward P/E ratio of 1.94 and 14.42, respectively. Price/sales for the same period is 4.79 while EPS is $2.39. Currently there are 19 analysts that rate ORCL a ‘Buy’, 15 rate it a ‘Hold’. 2 analysts rate it a ‘Sell’. ORCL has a median Wall Street price target of $48.00 with a high target of $52.00.

Investment analysts at Nomura initiated coverage on shares of Retrophin, Inc. (RTRX) in a note issued to investors on Monday. The firm set a ‘Buy’ rating and $31 price target on the stock. The firm’s price target would suggest a potential upside of 29% from the stock’s current price.

RTRX shares recently gained $2.02 to $23.89. In the past 52 weeks, shares of San Diego, California-based biopharmaceutical company have traded between a low of $7.85 and a high of $24.71. Shares are up 11.87% year-over-year and 78.68% year-to-date.

Nomura initiated coverage of Tekmira Pharmaceuticals Corp (TKMR) with a ‘Buy’ rating and a $32 price target, which represents expected upside of 84.50%.

TKMR shares recently lost $0.22 to $17.35. The stock is down more than 22% year-over-year and has gained roughly 16% year-to-date. In the past 52 weeks, shares of Tekmira have traded between a low of $8.86 and a high of $29.93.

Tekmira Pharmaceuticals Corp closed Friday at $17.57. The name has a total market cap of $810 million.

Ambarella, Inc. (AMBA) was reiterated a ‘Buy’ by Canaccord Genuity analysts on Monday. The broker also raised its price target on the stock to $81 from $74.

On valuation measures, AMBA shares are currently priced at 47.10x this year’s forecasted earnings, which makes them expensive compared to the industry’s 20.65x earnings multiple. Ticker has a forward P/E of 26.79 and t-12 price-to-sales ratio of 9.85. EPS for the same period is 1.57.

In the past 52 weeks, shares of the New York-based firm have traded between a low of $21.60 and a high of $74.20 and are now at $73.77. Shares are up 168.10% year-over-year ; up 38.70% year-to-date.

Be the first to comment

Leave a Reply

Your email address will not be published.


*